James Smith
Roger Sanchez
James Smith- pharma
- October 14, 2026
- 0 views
FDA Approval Pill: Worth a Proven $400M+ Opportunity
FDA approval pill could revolutionize treatment and is projected to generate over $400 million in revenue.
- James Smith
- pharma
- October 9, 2026
- 14 views
Cancer Drug Prices: Clear Path to 70% Savings Ahead
Cancer drug prices could see a significant drop of up to 70% due to government action.
- James Smith
- pharma
- October 7, 2026
- 12 views
Medexus Specialty Drug Launches: A Smart Move for Growth
Medexus specialty drug launches are gaining attention for their potential impact on the market.
- James Smith
- pharma
- October 1, 2026
- 17 views
Sudarshan Chemical’s acquisition is a Smart Move for Growth
Sudarshan Chemical acquisition marks a significant investment in Sudarshan Colorants, enhancing market presence and potential.
- James Smith
- pharma
- September 29, 2026
- 19 views
FDA Approval Bone Drug: Teva’s Proven New Treatment
FDA approval bone drug marks a significant advancement in treatment options.
- James Smith
- pharma
- September 24, 2026
- 25 views
Generic Zofran Launch: A Smart Move for Oncology Care
Generic Zofran launch expands oncology supportive care options in Canada.
- James Smith
- Pharma News
- September 21, 2026
- 27 views
H. Pylori therapy kit: Proven Safe Solution for Patients
H. Pylori therapy kit has received DCGI approval, ensuring a proven safe solution for effective treatment.
- James Smith
- Business Strategy
- September 18, 2026
- 34 views
MTR Foods growth strategy: Proven ways to boost profits
MTR Foods growth strategy is essential for understanding how Orkla India plans to expand through premiumisation and acquisitions.
- James Smith
- Politics
- September 10, 2026
- 41 views
Justice Minister Nominee’s Clear Path to Approval
Justice Minister Nominee seeks approval during parliamentary audit.
- James Smith
- Politics
- September 8, 2026
- 38 views
Is Trump Renaming New Mexico the Worst Idea Ever?
Trump renaming New Mexico has sparked controversy among Democrats.